Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients-Reference-Cited by-同舟云学术

Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients

Published:2013-10-02 Issue:6 Volume:16 Page:548-554
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Sánchez-Muñoz A.,Plata-Fernández Y.,Fernández M.,Jaén-Morago A.,Fernández-Navarro M.,de la Torre-Cabrera C.,Ramirez-Tortosa C.,Pascual J.,Alba E.,Sánchez-Rovira P.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-013-1116-z.pdf

Reference30 articles.

1. Perou CM, Sorlie T, Eisen MD, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747–52.

2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.

3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–23.

4. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–85.

5. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers;Future Oncology;2023-01

2. Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study;The Breast Journal;2022-11-29

3. Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis;BJS Open;2022-05-02

4. Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer;International Journal of Clinical Oncology;2022-04-10

5. Special Clinical Settings: Tumors Arising in Pregnancy, Pregnancy-Like (Pseudolactational) Proliferations, Breast Carcinoma in the Pre-neoadjuvant Chemotherapy Setting, Recurrent Breast Carcinoma, and Inflammatory Breast Carcinoma;A Comprehensive Guide to Core Needle Biopsies of the Breast;2022